Uganda’s QCI to invest $80m in AIDS and anti-malarial drug capacity
Ugandan drugmaker Quality Chemicals Industries (QCI) will invest $80m in manufacturing operations to boost capacity for the production of generic AIDS and malaria drugs.
The investment, which will take place over the next two years according to a Bloomberg report, will begin with a $30m expansion of its facility in the capital Kampala with funding provided by shareholders and the sale of new stock.
The second phase of the project, which will also be funded by shareholders, will see the addition of a brand new line for the production of pharmaceutical ingredients according to QCI marketing manager George Baguma who spoke with the newsier.
One of QCI’s biggest shareholders is Indian drugmaker Cipla, for which the Ugandan firm produces the combination antiretroviral drug Duovir-N.
